GET DAILY SIGNALSInspire Medical Systems (INSP) Stock Climbs +11% Over 30 Days Amid Broader Recovery
Key Takeaways
- Inspire Medical Systems (INSP) shares climbed roughly 11% over the trailing 30 days, moving from about $61.80 to near $68.66.
- The advance extends a broader recovery, with the stock up more than 50% over the trailing three months after a difficult first half of the year.
- Investor confidence has been supported by a second-quarter earnings beat, raised 2026 guidance, and the new Project Horizon growth initiative.
- Analyst upgrades and proposed 2027 CMS reimbursement increases for the Inspire V procedure reinforced the positive tone.
- Coding and reimbursement disruptions, along with emerging competition, remain the primary risks to monitor.
Company Overview: Inspire Medical Systems and Its Market Position
Inspire Medical Systems (INSP) develops and commercializes minimally invasive neurostimulation treatments for moderate to severe obstructive sleep apnea. Its Inspire therapy represents the first FDA-approved hypoglossal nerve stimulation technology for patients who cannot tolerate or do not benefit from CPAP therapy. The current Inspire V system incorporates a respiratory sensor into the neurostimulator, which simplifies the implant procedure. The company sells directly to hospitals and ambulatory surgery centers in the United States, select European markets, and Japan, and has treated more than 140,000 patients since inception. It maintains a first-mover position in this segment, though competition is growing from companies such as LivaNova (LIVN) and Nyxoah (NYXH).
INSP Stock Performance: Recent 30-Day Move Compared to the Quarter
Over the trailing 30 days, INSP advanced approximately 11%, rising from a closing level near $61.80 to about $68.66. The stock touched an intraday high near $78.80 in mid-September before some profit-taking led to consolidation. This gain forms part of a larger recovery. Over the trailing three months, INSP has climbed more than 50% from roughly $43 in late June, reversing much of the earlier decline after the company lowered its 2026 outlook.
Factors Supporting the 30-Day Advance in INSP Shares
The recent 30-day gain largely reflects sustained positive sentiment after the second-quarter results reported in early August. Inspire delivered a beat-and-raise quarter, with revenue of $200.6 million and adjusted earnings of $0.14 per share both exceeding consensus estimates, and it raised full-year 2026 guidance for revenue, adjusted operating margin, and adjusted earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Analyst actions added to the momentum, including an upgrade to Outperform from Oppenheimer with an $85 price target and price-target increases from RBC, Baird, and Piper Sandler. Investors responded as well to CMS proposed 2027 reimbursement increases for the Inspire V procedure, including a 12% rise for hospital outpatient settings and a 15% increase for ambulatory surgery centers.
Drivers Behind the Three-Month Recovery Trend
The three-month uptrend reflects a broader shift in sentiment. Earlier in 2026, coding and reimbursement disruptions related to the phase-out of a key CPT code and the WISeR program slowed U.S. procedure activity and led the company to cut its 2026 outlook, which weighed on the stock. The narrative began to turn in June with the presentation of full Inspire V trial results and cardiovascular-outcome data at the American Academy of Sleep Medicine conference. The inflection point came in early August when second-quarter results beat expectations, management raised guidance, and the company launched Project Horizon, a restructuring plan expected to create about $30 million in annualized growth investment capacity. The stock rose roughly 18% in a single session after the report and continued climbing through September.
Key Items to Monitor for INSP Going Forward
Investors should track several factors in the months ahead. Third-quarter results will test whether the company can deliver the sequential improvement management has guided toward, with third-quarter revenue expected to decline 8% to 10% year over year. Final 2027 CMS reimbursement rates, expected in November, will clarify whether the proposed facility-rate increases are confirmed. The company’s revised application for a new Category 1 CPT code, targeting implementation on January 1, 2028, remains a key long-term catalyst. Execution of Project Horizon, including restructuring charges, and the pace of prior-authorization improvement will also be closely watched. Finally, competition from LivaNova’s (LIVN) recently approved aura6000 system and Nyxoah’s (NYXH) Genio platform could influence market-share dynamics. From what I see, these elements will shape the trajectory in the near term.
AI Tools in My Research Process
I often turn to Tickeron’s AI Trading Bots when evaluating systematic approaches to stocks like this one. The platform offers a range of strategies across different timeframes and performance metrics, allowing users to explore data-driven options that align with their own analysis. In this case, reviewing the bots helped confirm broader market patterns without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for INSP turns negative, indicating new downward trend
INSP saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 71 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 59 cases where INSP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 34 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
INSP moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Bullish Trend Analysis
The 50-day moving average for INSP moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSP advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 144 of 199 cases where INSP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. INSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.385) is normal, around the industry mean (4.209). P/E Ratio (14.837) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.375) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices
Advertisement